Jon Najarian: Inhibrx Biosciences gains after hours on phase 2 trial update

Jon Najarian: Inhibrx Biosciences gains after hours on phase 2 trial update
Inhibrx up after trial news

Jon Najarian, co-founder of Market Rebellion at https://x.com/jonnajarian, reports that Inhibrx Biosciences rose 7 percent in after-hours trading. The company announced it will release interim results on May 11 from its phase 2 trial of INBRX-106 for first-line head and neck squamous cell carcinoma.

Najarian notes that optimism is growing regarding the anticipated results.

Najarian has previously covered major deals in sports and finance, including Big12’s five-year private capital agreement with RedBird Capital. He has also commented on high-profile disputes involving net worth disclosures and property valuations. The latest move in Inhibrx Biosciences follows a series of timely updates on significant market developments.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.